Induced Pluripotent Stem Cells (iPSCs) hold promising hope for therapeutic solutions for diseases without ethical issues. We’ve seen the first human iPSC clinical trials back in August of 2014, and we’re expecting to see more clinical trials being launched for a variety of diseases. This will propel the progress being made towards opening clinical practices which in turn will drive the growth of both the clinical and the research markets.
Continue reading this report plus more!
Monthly Access $9.99
Single Paper $59.99